drug_type
RELEVANT_DRUG
intervention_type
Biologic monoclonal antibody (anti-TNF), intravenous
drug_description
Chimeric IgG1 anti–TNF-α monoclonal antibody that binds soluble and transmembrane TNF-α to inhibit TNFR1/2 signaling, thereby reducing NF-κB/MAPK activation, pro-inflammatory cytokines (e.g., IL-1, IL-6), adhesion molecule expression, and leukocyte trafficking; can induce apoptosis/ADCC of TNF-expressing cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
CT-P13
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
Chimeric IgG1 monoclonal antibody against TNF-alpha that binds soluble and transmembrane TNF-alpha to block TNFR1/2 signaling, suppressing NF-kB/MAPK pathways, pro-inflammatory cytokines, adhesion molecules, and leukocyte trafficking; can also mediate ADCC/complement effects and apoptosis of TNF-expressing cells.
drug_name
Infliximab (CT-P13, Remsima)
nct_id_drug_ref
NCT06051253